Original title: Rosuvastatin calcium in acute coronary sydromes Reference: Aggarwal, R. et al, Expert Opinion on Pharmacotherapy , Volume 14, Number 9, June 2013 , pp. 1215-1227(13).
Lowering cholesterol of low density lipoproteins (LDL-C) by reducing inhibitors of 3-hydroxy-3-metilgutaril coenzyme A (HMGCoA) statins has proven advantageous for the survival of patients with acute coronary syndrome (ACS). These patients still have a significant risk of cardiovascular death and non-fatal myocardial infarction despite high compliance with secondary prevention treatments indicated by current guidelines. In this sense, the article warns that there remains a need to assess the possible positive effects of more intensive lowering of LDL-C after the presentation of ACS. Rosuvastatin is the most potent statins currently available and has some unique pharmacological properties that may offer advantages to these patients.
The authors conducted a MEDLINE literature search to identify studies of Rosuvastatin and the use of statins in acute coronary syndrome that had been published in English. In this analysis the pharmacology of Rosuvastatin was described and its efficacy and tolerability were analyzed. Likewise they evaluated published studies on the treatment of ASC with statins and offered an opinion about the use of Rosuvastatin with ASC. After analysis, the authors determined that evidence is available from clinical studies to confirm the effectiveness of reducing LDL-C and tolerability suitable for high-dose Rosuvastatin in acute coronary syndrome. Although there are logical theoretical reasons to take into account about the early use of high-dose of Rosuvastatin in ASC, the level of evidence available still justifies a complete change regarding the current treatment pattern.
Source: Medcenter.com, the leading Latin American medical portal
SOLACI.ORG